These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1966601)

  • 1. 5-HT3 receptor antagonists attenuate dopamine-induced hyperactivity in the rat.
    Costall B; Domeney AM; Naylor RJ
    Neuroreport; 1990 Sep; 1(1):77-80. PubMed ID: 1966601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-HT3 receptor antagonists attenuate cocaine-induced locomotion in mice.
    Reith ME
    Eur J Pharmacol; 1990 Sep; 186(2-3):327-30. PubMed ID: 2289534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emetic activity of zacopride in ferrets and its antagonism by pharmacological agents.
    Sancilio LF; Pinkus LM; Jackson CB; Munson HR
    Eur J Pharmacol; 1990 Jun; 181(3):303-6. PubMed ID: 2384137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The differential activities of R (+)- and S(-)-zacopride as 5-HT3 receptor antagonists.
    Barnes JM; Barnes NM; Costall B; Domeney AM; Johnson DN; Kelly ME; Munson HR; Naylor RJ; Young R
    Pharmacol Biochem Behav; 1990 Dec; 37(4):717-27. PubMed ID: 2128757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron.
    Barnes JM; Barnes NM
    Biochem Pharmacol; 1993 May; 45(10):2155-8. PubMed ID: 8390263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of 5-HT3 receptor antagonists on gastrointestinal motility].
    Yoshida N; Ito T; Karasawa T; Iwanaga H; Mizumoto A; Ito A
    Nihon Heikatsukin Gakkai Zasshi; 1989 Dec; 25(6):315-9. PubMed ID: 2562028
    [No Abstract]   [Full Text] [Related]  

  • 7. Preliminary evidence for the involvement of the putative 5-HT4 receptor in zacopride- and copper sulphate-induced vomiting in the ferret.
    Bhandari P; Andrews PL
    Eur J Pharmacol; 1991 Nov; 204(3):273-80. PubMed ID: 1663456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of 5-HT3 receptor by 1-phenylbiguanide increases dopamine release in the rat nucleus accumbens.
    Chen JP; van Praag HM; Gardner EL
    Brain Res; 1991 Mar; 543(2):354-7. PubMed ID: 1711914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-HT3 receptor antagonists block cocaine-induced locomotion via a PCPA-sensitive mechanism.
    Svingos AL; Hitzemann R
    Pharmacol Biochem Behav; 1992 Nov; 43(3):871-9. PubMed ID: 1448481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 5-HT3 receptor antagonists LY 277359 and granisetron potentiate the suppressant action of apomorphine on the basal firing rate of ventral tegmental dopamine cells.
    Minabe Y; Ashby CR; Schwartz JE; Wang RY
    Eur J Pharmacol; 1991 Dec; 209(3):143-50. PubMed ID: 1665793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-HT3 receptor antagonists inhibit morphine-induced stimulation of mesolimbic dopamine release and function in the rat.
    Pei Q; Zetterström T; Leslie RA; Grahame-Smith DG
    Eur J Pharmacol; 1993 Jan; 230(1):63-8. PubMed ID: 8381355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 5-HT3 antagonist zacopride attenuates cocaine-induced increases in extracellular dopamine in rat nucleus accumbens.
    McNeish CS; Svingos AL; Hitzemann R; Strecker RE
    Pharmacol Biochem Behav; 1993 Aug; 45(4):759-63. PubMed ID: 8415815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the 5-HT3 receptor antagonist properties of ICS 205-930, GR38032F and zacopride.
    Cohen ML; Bloomquist W; Gidda JS; Lacefield W
    J Pharmacol Exp Ther; 1989 Jan; 248(1):197-201. PubMed ID: 2521513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response heterogeneity of 5-HT3 receptor antagonists in a rat visceral hypersensitivity model.
    Langlois A; Pascaud X; Junien JL; Dahl SG; Rivière PJ
    Eur J Pharmacol; 1996 Dec; 318(1):141-4. PubMed ID: 9007525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of potencies of 5-HT3 receptor antagonists at inhibiting aversive behavior to illumination and the von Bezold-Jarisch reflex in the mouse.
    Eglen RM; Lee CH; Khabbaz M; Fontana DJ; Daniels S; Kilfoil T; Wong EH
    Neuropharmacology; 1994 Feb; 33(2):227-34. PubMed ID: 8035908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 5-hydroxytryptamine 3 receptor antagonists on gastrointestinal motor activity in conscious dogs.
    Yoshida N; Mizumoto A; Iwanaga Y; Itoh Z
    J Pharmacol Exp Ther; 1991 Jan; 256(1):272-8. PubMed ID: 1846418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain.
    Costall B; Domeney AM; Naylor RJ; Tyers MB
    Br J Pharmacol; 1987 Dec; 92(4):881-94. PubMed ID: 2962686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zacopride and BRL 24924 induce an increase in EEG-energy in rats.
    Boddeke HW; Kalkman HO
    Br J Pharmacol; 1990 Oct; 101(2):281-4. PubMed ID: 2257436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zacopride, a potent 5-HT3 antagonist.
    Smith WW; Sancilio LF; Owera-Atepo JB; Naylor RJ; Lambert L
    J Pharm Pharmacol; 1988 Apr; 40(4):301-2. PubMed ID: 2900319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiles of interaction of R(+)/S(-)-zacopride and anxiolytic agents in a mouse model.
    Barnes NM; Cheng CH; Costall B; Ge J; Kelly ME; Naylor RJ
    Eur J Pharmacol; 1992 Jul; 218(1):91-100. PubMed ID: 1356807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.